The Latest Breaking News from FDA

The weight-loss and diabetes injectables have seen a surge in demand primarily in the U.S., buoying Novo Nordisk’s profits in the first half of 2023.

Maybe it's not a full-blown summer surge but COVID numbers are ticking up. For those with concerns due to personal risk factors or the start of the school year, the booster question is top of mind.

Eli Lilly stock has sold off alongside the broader market over the last week, undercutting its moving averages. Is LLY stock a sell?

Postpartum depression affects as many as 1 in 7 women in the U.S., though there are just two treatments approved for it. Experts say the newest could be a game-changer — depending on its price tag.

With the advent of advanced medications and the increasing need for personalized treatments, the pharmaceutical industry looks well-poised for long-term growth. Therefore, it could be worth looking into three fundamentally sound pharma stocks, Pfizer (PFE), Sanofi (SNY), and GSK plc (GSK), that are offering significant value. Read more….

A policy that wasn't rooted solely in science is diminished, but certain barriers to blood donation still remain

Astellas Pharma won FDA approval for a rival to Apellis Pharmaceuticals' eye-disease treatment and APLS stock plunged Monday.

Sage stock plummeted Monday after the FDA approved its drug, Zurzuvae, in postpartum depression, but not major depressive disorder.

Donald Trump's legal team has until 5:00 p.m. to respond to prosecutors' request for a protective order. The FDA has approved the first pill to treat postpartum depression.